RDIF和ChemRar宣布增加用于治疗冠状病毒的阿维法韦的生产，并开始出口交货
RDIF和ChemRar生产了前100,000疗程的阿维法韦
阿维法韦于6月在俄罗斯的35个地区交付
50多个国家表示有兴趣进口阿维法韦
莫斯科，2020年7月2日-
俄罗斯直接投资基金（RDIF），俄罗斯主权财富基金和ChemRar Group
在6月份生产了俄罗斯冠状病毒药物阿维法韦的前100,000个疗程，大大超过了最初计划的60,000个疗程的生产水平。
六月
已交付给俄罗斯的35个地区和白俄罗斯共和国。
Agreement
has also been reached for deliveries of Avifavir to the Republic of Kazakhstan in the near future. In total, more than 100,000 courses will be produced in July.
The joint venture established by RDIF and ChemRar Group
provided an additional opportunity to increase production capacity threefold, up to 300,000 courses per month, which will satisfy domestic demand for Avifavir in the Russian Federation and enable the start of supplies to the international market.
On May 29, 2020, Avifavir
received a registration certificate from Russia’s Ministry of Health and became the first Favipiravir-based drug in the world approved for the treatment of COVID-19.
On June 3, 2020, the Ministry of Health
included Avifavir in the latest seventh edition of the guidelines for the prevention, diagnosis and treatment of new coronavirus infection COVID-19.
Avifavir has proven effective in clinical trials, disrupting the reproduction mechanisms of coronavirus.
RDIF and ChemRar
have seen significant demand for the drug from abroad. In particular, negotiations are underway on the supply of Avifavir to a number of Latin American countries.
In addition, CIS countries, the Middle East and other global regions have expressed interest in acquiring Avifavir.